<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666494</url>
  </required_header>
  <id_info>
    <org_study_id>Bio 18-19</org_study_id>
    <nct_id>NCT03666494</nct_id>
  </id_info>
  <brief_title>Ketamine Co-induction for Patients With Major Depressive Disorder</brief_title>
  <official_title>Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ketamine hydrochloride, an anesthetic medication, has been demonstrated to acutely and
      rapidly improve depressive symptoms but not yet been adequately studied for this effect when
      used as part of a general anesthetic for surgery. This proposed single-centre,
      double-blinded, randomized clinical trial of adult patients with depression presenting for
      gynecologic surgery would compare severity of depressive symptoms between patients receiving
      and not receiving ketamine as part of their general anesthetic.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>At time of discharge from post-anesthetic care unit, until 3 hours post operatvie</time_frame>
    <description>Severity of depression as measured by Montgomery-Asberg Depression Rating Scale (MADRS), 0-60 where 0 to 6 is normal, 7-19 is mild depression, 20-34 is moderate depression, and &gt;34 is severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Severity of depression as measured by Montgomery-Asberg Depression Rating Scale (MADRS), 0-60 where 0 to 6 is normal, 7-19 is mild depression, 20-34 is moderate depression, and &gt;34 is severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>7-days post-operative</time_frame>
    <description>Severity of depression as measured by Montgomery-Asberg Depression Rating Scale (MADRS), 0-60 where 0 to 6 is normal, 7-19 is mild depression, 20-34 is moderate depression, and &gt;34 is severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression Severity</measure>
    <time_frame>30-days post-operative</time_frame>
    <description>Severity of depression as measured by Montgomery-Asberg Depression Rating Scale (MADRS), 0-60 where 0 to 6 is normal, 7-19 is mild depression, 20-34 is moderate depression, and &gt;34 is severe depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Pre-operatively</time_frame>
    <description>Verbally reported numeric pain score (out of 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>Upon discharge from PACU, up to 3 hours postoperative</time_frame>
    <description>Verbally reported numeric pain score (out of 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>72 hours post-opertaive</time_frame>
    <description>Verbally reported numeric pain score (out of 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>7-days post-op</time_frame>
    <description>Verbally reported numeric pain score (out of 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score</measure>
    <time_frame>30-days post-op</time_frame>
    <description>Verbally reported numeric pain score (out of 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia use</measure>
    <time_frame>Pre-operatively</time_frame>
    <description>Morphine equivalents (in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia use</measure>
    <time_frame>Upon discharge from PACU, up to 3 hours postoperative</time_frame>
    <description>Morphine equivalents (in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia use</measure>
    <time_frame>72 hours post-operative</time_frame>
    <description>Morphine equivalents (in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia use</measure>
    <time_frame>7-days post-operative</time_frame>
    <description>Morphine equivalents (in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia use</measure>
    <time_frame>30-days post-operative</time_frame>
    <description>Morphine equivalents (in milligrams)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ketamine</condition>
  <condition>Depression</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As part of the patient's anesthetic induction, they will receive propofol and fentanyl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine Hydrochloride</intervention_name>
    <description>As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.</description>
    <arm_group_label>Ketamine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>As part of the patient's anesthetic induction, they will receive propofol.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Ketamine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>As part of the patient's anesthetic induction, they will receive fentanyl.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Ketamine Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of major depressive disorder

          -  Presentation for gynecologic surgery requiring a general anesthetic

        Exclusion Criteria:

          -  Marked co-morbid cardiovascular disease

          -  Marked co-morbid respiratory disease

          -  History of intracranial hypertension

          -  History of seizures

          -  ASA Physical Status Classification IV or greater

          -  History of psychosis

          -  Current pregnancy

          -  Contraindication to ketamine administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Gamble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Gamble, MD</last_name>
    <phone>306-655-1183</phone>
    <email>j_gamble@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordon Steeg, MD</last_name>
    <phone>306-222-9782</phone>
    <email>jordon.steeg@usask.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg. 2002 Jul;95(1):114-8, table of contents.</citation>
    <PMID>12088953</PMID>
  </reference>
  <reference>
    <citation>McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015 Mar;45(4):693-704. doi: 10.1017/S0033291714001603. Epub 2014 Jul 10. Review.</citation>
    <PMID>25010396</PMID>
  </reference>
  <reference>
    <citation>Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015 Mar-Apr;37(2):178-84. doi: 10.1016/j.genhosppsych.2015.01.003. Epub 2015 Jan 15. Review.</citation>
    <PMID>25698228</PMID>
  </reference>
  <reference>
    <citation>Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014 Sep;231(18):3663-76. doi: 10.1007/s00213-014-3664-5. Epub 2014 Jul 20. Review.</citation>
    <PMID>25038867</PMID>
  </reference>
  <reference>
    <citation>Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31. doi: 10.1017/S1461145711000629. Epub 2011 May 5. Retraction in: Int J Neuropsychopharmacol. 2017 Jul 1;20(7):611.</citation>
    <PMID>21557878</PMID>
  </reference>
  <reference>
    <citation>Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol. 2014 Apr;4(2):75-99. doi: 10.1177/2045125313507739. Review.</citation>
    <PMID>24688759</PMID>
  </reference>
  <reference>
    <citation>Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4.</citation>
    <PMID>10686270</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

